发布求助
文献互助 智能选刊 最新文献

Future Virology最新文献

筛选
英文 中文
A review: cellular attachment and entry factors of human tumor-associated viruses 综述：人类肿瘤相关病毒的细胞附着和进入因子
IF 3.1 4区 医学
Future Virology Pub Date : 2024-05-01 DOI: 10.2217/fvl-2023-0210
Duo Shi, Yan Zhang, Bin Luo
{"title":"A review: cellular attachment and entry factors of human tumor-associated viruses","authors":"Duo Shi, Yan Zhang, Bin Luo","doi":"10.2217/fvl-2023-0210","DOIUrl":"https://doi.org/10.2217/fvl-2023-0210","url":null,"abstract":"Tumorigenesis is a major hidden danger to human health, with over nine million people worldwide dying from tumors annually. About two-thirds of tumors are caused by persistent infection with oncogenic viruses. Since the human carcinogenic Epstein-Barr virus (EBV) was first discovered, seven human carcinogenic viruses have been identified. Thus, understanding the role of viruses in tumorigenesis is crucial in cancer research. Classical viral infections arise from interactions between viral capsid or envelope proteins and cell surface receptors, which are subsequently internalized through envelope fusion or endocytosis. In this study, we summarize processes by which seven carcinogenic viruses attach to target cells and the co-factors involved.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141050037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploration of the cross-immunity between SARS-CoV and SARS-CoV-2 in mice 探索小鼠体内 SARS-CoV 和 SARS-CoV-2 的交叉免疫性
IF 3.1 4区 医学
Future Virology Pub Date : 2024-03-26 DOI: 10.2217/fvl-2023-0212
Shuhui Wang, Li Ren, Ying Liu, Xiuli Shen, Yanling Hao, Yiming Shao
{"title":"Exploration of the cross-immunity between SARS-CoV and SARS-CoV-2 in mice","authors":"Shuhui Wang, Li Ren, Ying Liu, Xiuli Shen, Yanling Hao, Yiming Shao","doi":"10.2217/fvl-2023-0212","DOIUrl":"https://doi.org/10.2217/fvl-2023-0212","url":null,"abstract":"Aim: This study aimed to develop a universal vaccine that can effectively address future outbreaks of coronavirus infections. Materials & methods: We developed recombinant DNA vaccines and vaccinia vector vaccines specific for SARS-CoV and SARS-CoV-2 and evaluated them in BALB/c mice. Both cellular and humoral immune responses were analyzed. Results: Compared with those immunized with the SARS-CoV or SARS-CoV-2 vaccine alone, the cross-immune group exhibited a 21.2-fold increase in cellular immune response, an over 80-fold increase in binding antibodies and a 136.7-fold increase in neutralizing antibodies. The combination of recombinant DNA and vaccinia vaccines induced a stronger immune response than DNA vaccine immunization alone. Conclusion: This study demonstrated that cross-immunization with different coronaviruses can induce a broad immune response.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140377853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
It's time for a booster: here's your 19th dose of Future Virology! 是时候来点 "强心剂 "了：这是您的第 19 剂 "未来病毒学"！
IF 3.1 4区 医学
Future Virology Pub Date : 2024-03-20 DOI: 10.2217/fvl-2024-0030
Ellen Porter
{"title":"It's time for a booster: here's your 19th dose of Future Virology!","authors":"Ellen Porter","doi":"10.2217/fvl-2024-0030","DOIUrl":"https://doi.org/10.2217/fvl-2024-0030","url":null,"abstract":"","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140225807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-COVID-19 symptom burden: treatment with Forsythiae Fructus COVID-19 后的症状负担：连翘疗法
IF 3.1 4区 医学
Future Virology Pub Date : 2024-03-20 DOI: 10.2217/fvl-2023-0190
Yan Zhao, Xin Gao, Guangping Wang, Jiali Ren, Weisan Chen, Ying Zhao, Xiankuan Li, Jian Zhang
{"title":"Post-COVID-19 symptom burden: treatment with Forsythiae Fructus","authors":"Yan Zhao, Xin Gao, Guangping Wang, Jiali Ren, Weisan Chen, Ying Zhao, Xiankuan Li, Jian Zhang","doi":"10.2217/fvl-2023-0190","DOIUrl":"https://doi.org/10.2217/fvl-2023-0190","url":null,"abstract":"COVID-19 is a widespread illness that affects human life. Following infection, many patients may suffer long-term sequelae of COVID-19. Forsythiae Fructus is a popular herbal treatment for the common cold and flu. According to studies, the active components in Forsythiae Fructus have potent antiviral properties and can treat various diseases by influencing several pathways. This article explores the mechanism of action and effectiveness of the active components in Forsythiae Fructus for treating COVID-19 through a literature review and network pharmacology techniques, emphasizing their effects on sequelae.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140227778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conference proceedings from the 26th Bangkok International Symposium on HIV Medicine 第 26 届曼谷国际艾滋病医学研讨会会议录
IF 3.1 4区 医学
Future Virology Pub Date : 2024-03-18 DOI: 10.2217/fvl-2024-0016
P. Ohata, Stephen J Kerr, Hay Mar Su Lwin, S. Gatechompol, Siwat Thammapiwan, S. Ubolyam, O. Putcharoen, Jeremy Ross, Raja Iskandar Shah Raja Azwa, Nagalingeswaran Kumarasamy, T. Puthanakit, D. Colby, P. Phanuphak, A. Avihingsanon
{"title":"Conference proceedings from the 26th Bangkok International Symposium on HIV Medicine","authors":"P. Ohata, Stephen J Kerr, Hay Mar Su Lwin, S. Gatechompol, Siwat Thammapiwan, S. Ubolyam, O. Putcharoen, Jeremy Ross, Raja Iskandar Shah Raja Azwa, Nagalingeswaran Kumarasamy, T. Puthanakit, D. Colby, P. Phanuphak, A. Avihingsanon","doi":"10.2217/fvl-2024-0016","DOIUrl":"https://doi.org/10.2217/fvl-2024-0016","url":null,"abstract":"The first Bangkok International Symposium on HIV Medicine was launched in January 1998 with the aim to provide up-to-date information on HIV to professional heathcare workers in Thailand and surrounding countries who cannot afford to attend conferences abroad. After several virtual conferences during the COVID-19 pandemic, this is the second face-to-face meeting held in Bangkok from 17 to 19 January 2024. There were a total of six plenary sessions each morning and two afternoon workshops on Wednesday and Thursday. The symposium had expert speakers from Thailand, Australia, Taiwan, India, Malaysia, the UK, the USA, Japan, Singapore, the Philippines and Vietnam.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140232144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Direct virus capture assay for label-free detection of SARS-CoV-2 virions using laser microscopy 利用激光显微镜无标记检测 SARS-CoV-2 病毒的直接病毒捕获分析法
IF 3.1 4区 医学
Future Virology Pub Date : 2024-03-18 DOI: 10.2139/ssrn.4494421
Alessandro Pennesi, G. Ferrari, Federica Giardina, Sara Piselli, Roberto Lo Savio, Adolfo Carloni, S. Paolucci, F. Baldanti
{"title":"Direct virus capture assay for label-free detection of SARS-CoV-2 virions using laser microscopy","authors":"Alessandro Pennesi, G. Ferrari, Federica Giardina, Sara Piselli, Roberto Lo Savio, Adolfo Carloni, S. Paolucci, F. Baldanti","doi":"10.2139/ssrn.4494421","DOIUrl":"https://doi.org/10.2139/ssrn.4494421","url":null,"abstract":"Aim: To evaluate a label-free and variant-independent assay called direct virus capture (DVC) for detection of intact SARS-CoV-2 virions through light scattering, utilizing an optical inverted laser microscope called nano eye device virus detector (NED-VD). Methods: The DVC assay involves the interaction between ACE2 receptors printed on a glass coverslip substrate, and the S protein on the outer surface of virions. The study was conducted using 191 human swab specimens. Results: In comparison to the RT-PCR assay, the DVC method achieved a sensitivity of 40.5%, specificity of 90.4% and accuracy of 46%. Conclusion: The study presents a promising qualitative pre-screening test to evaluate the presence of whole virions and reduce the number of PCR tests.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140233378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decreased efficacy of sofosbuvir/velpatasvir in HIV patients coinfected with HCV genotype 3b 索非布韦/韦帕他韦对合并感染丙型肝炎病毒（HCV）基因型 3b 的艾滋病患者的疗效降低
IF 3.1 4区 医学
Future Virology Pub Date : 2024-02-28 DOI: 10.2217/fvl-2023-0112
Jingdi Zhou, Fada Wang, Lanzhi Li, Jing-Yu Li, En-Qiang Chen
{"title":"Decreased efficacy of sofosbuvir/velpatasvir in HIV patients coinfected with HCV genotype 3b","authors":"Jingdi Zhou, Fada Wang, Lanzhi Li, Jing-Yu Li, En-Qiang Chen","doi":"10.2217/fvl-2023-0112","DOIUrl":"https://doi.org/10.2217/fvl-2023-0112","url":null,"abstract":"Aim: To retrospectively assess the efficacy and safety of sofosbuvir/velpatasvir for hepatitis C virus (HCV) genotype 3b in HIV-infected patients receiving antiretroviral therapy (ART) treatment of lamivudine/tenofovir disoproxil fumarate/efavirenz. Methods: The primary end point of HCV treatment was estimated by sustained virologic response 12 weeks after treatment (SVR12). Results: Sixteen subjects who were followed up for 48 weeks after treatment were included. The SVR12 and SVR48 were 87.5% (95% CI: 60.4–97.8%) and 81.3% (95% CI: 53.7–95.0%), respectively. One patient experienced persistent low-level viremia of HIV after 12 weeks of treatment. Conclusion: Twelve weeks of SOF/VEL is safe but has limited efficacy for HCV GT3b in HIV-infected patients receiving ART regimen including efavirenz, especially among patients with baseline HCV RNA≥6.0 log10 IU/ml.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140419257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GSTP, GSTT1, XRCC1 and CASP8 genetic variations are associated with human papillomavirus in women with cervical cancer from Zimbabwe 津巴布韦宫颈癌妇女的 GSTP、GSTT1、XRCC1 和 CASP8 基因变异与人类乳头瘤病毒的关系
IF 3.1 4区 医学
Future Virology Pub Date : 2024-02-26 DOI: 10.2217/fvl-2023-0154
Oppah Kuguyo, Racheal S Dube Mandishora, N. Soko, Takudzwa Magwaku, A. Matimba, C. Dandara
{"title":"GSTP, GSTT1, XRCC1 and CASP8 genetic variations are associated with human papillomavirus in women with cervical cancer from Zimbabwe","authors":"Oppah Kuguyo, Racheal S Dube Mandishora, N. Soko, Takudzwa Magwaku, A. Matimba, C. Dandara","doi":"10.2217/fvl-2023-0154","DOIUrl":"https://doi.org/10.2217/fvl-2023-0154","url":null,"abstract":"Aim: Investigate the role of host genetic variations in high-risk human papillomaviruses (HR-HPVs). Methods: This cross-sectional study recruited 238 cervical cancer patients. Variants in transport (ABCC2), xenobiotic metabolism ( GSTP, GSTT1, GSTM1, NQO1), DNA repair ( ERCC1, XRCC1), immune response ( TLR4) and apoptosis ( CASP8, FASL, p53) genes were characterized. Tumor DNA was genotyped for 14 HR-HPVs. Results: GSTP rs1695GG, XRCC1 rs1799782TT and GSTT1 del/del were associated with HPV51 (odds ratio [OR]: 3.9; 95% confidence interval [CI]: 1.3–11.7; p = 0.02) and HPV58 (OR: 2.4; 95% CI: 1.2–5.8; p = 0.048), respectively. CASP8 rs3834129del/del was associated with HPV16/18 (OR: 2.7; 95% CI: 1.2–6.0; p = 0.017) and HPV monoinfections (OR: 2.3; 95% CI: 1.2–4.4; p = 0.008). Conclusion: GSTP, GSTT1, XRCC1 and CASP8 variants were associated with HPV-positivity. With further research, a genetic-based screening tool can be developed, to use with HPV vaccines toward preventing cervical cancer.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140429130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-life use of high-dose anakinra in patients with COVID-19 treated with remdesivir 在接受雷米替韦治疗的 COVID-19 患者中实际使用大剂量阿纳金雷
IF 3.1 4区 医学
Future Virology Pub Date : 2024-02-26 DOI: 10.2217/fvl-2023-0132
Roberta Monardo, A. Mastrangelo, Laura Galli, A. Tomelleri, V. Spagnuolo, C. Oltolini, Giacomo Ponta, C. Campochiaro, G. Cavalli, L. Dagna, F. Ciceri, Paola Cinque, P. Scarpellini, Antonella Castagna, M. Ripa
{"title":"Real-life use of high-dose anakinra in patients with COVID-19 treated with remdesivir","authors":"Roberta Monardo, A. Mastrangelo, Laura Galli, A. Tomelleri, V. Spagnuolo, C. Oltolini, Giacomo Ponta, C. Campochiaro, G. Cavalli, L. Dagna, F. Ciceri, Paola Cinque, P. Scarpellini, Antonella Castagna, M. Ripa","doi":"10.2217/fvl-2023-0132","DOIUrl":"https://doi.org/10.2217/fvl-2023-0132","url":null,"abstract":"Aim: Aim of this study was to evaluate the effect of anakinra (ANK) addition to remdesivir (RDV) on all-cause 28-day mortality in patients hospitalized with COVID-19. Patients & methods: ANK was administered intravenously at a dose of 5 mg/kg every 12 h in patients with severe respiratory failure and pronounced inflammatory status. 58 patients were treated with RDV + ANK, 219 patients with RDV. Results: The estimate of mortality at 28 days was 17.2% in the RDV + ANK group and 21.4% in the RDV group. Median time to death was 14 days in the RDV + ANK group and 19 in the RDV group. Conclusion: Despite severe respiratory failure and pronounced inflammatory status, patients who received RDV + ANK had similar mortality compared with patients who received RDV.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140430481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human RSVA-ON1, the only genotype present during 2019–2020 winter season in Riyadh, Saudi Arabia: a retrospective study 沙特阿拉伯利雅得 2019-2020 年冬季唯一出现的人类 RSVA-ON1 基因型：一项回顾性研究
IF 3.1 4区 医学
Future Virology Pub Date : 2023-12-19 DOI: 10.2217/fvl-2023-0173
Anwar Ahmed, A. Alhetheel, Shama Parveen, F. Almajhdi, Noorah A. Alkubaisi, Muslim Mohammed Al-Saadi
{"title":"Human RSVA-ON1, the only genotype present during 2019–2020 winter season in Riyadh, Saudi Arabia: a retrospective study","authors":"Anwar Ahmed, A. Alhetheel, Shama Parveen, F. Almajhdi, Noorah A. Alkubaisi, Muslim Mohammed Al-Saadi","doi":"10.2217/fvl-2023-0173","DOIUrl":"https://doi.org/10.2217/fvl-2023-0173","url":null,"abstract":"Aim: The study aimed to analyze human respiratory syncytial virus (hRSV) strains in nasopharyngeal aspirates obtained retrospectively. Materials & methods: Clinical information of ARI patients (n = 53) was accessed and 2nd hypervariable region of G protein gene of RSV was sequenced and analyzed. Results: Cough (98.1%), fever 40 (75.4%) and shortness of breath 32 (60.3%) were the common symptom. Sequence determination (n = 45) categorized all the strains in ON1 genotype. Potential O- and N- glycosylation were observed at some sites and purifying selections were observed at 274 and 320 codon positions. Conclusion: The study reports replacement of other RSVA genotypes with ON1. The future course of studies should emphasize on clinical implications of presence of hRSVA-ON1 genotype in a given population.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138959903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信